Vericel Corporation (VCEL)
Largest Insider Buys in Sector
VCEL Stock Price History Chart
VCEL Stock Performance
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric …
Insider Activity of Vericel Corporation
Over the last 12 months, insiders at Vericel Corporation have bought $0 and sold $24.76M worth of Vericel Corporation stock.
On average, over the past 5 years, insiders at Vericel Corporation have bought $0 and sold $11.39M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,780 shares for transaction amount of $20,592 was made by Rubino Alan L (director) on 2018‑03‑16.
List of Insider Buy and Sell Transactions, Vericel Corporation
| 2024-12-04 | Sale | director | 2,600 0.0053% | $58.72 | $152,672 | -2.66% | ||
| 2024-12-02 | Sale | Chief Medical Officer | 10,000 0.0202% | $58.72 | $587,200 | -3.22% | ||
| 2024-11-22 | Sale | director | 2,500 0.0052% | $60.00 | $150,000 | -2.62% | ||
| 2024-11-14 | Sale | President and CEO | 17,500 0.036% | $53.93 | $943,775 | -2.69% | ||
| 2024-11-13 | Sale | President and CEO | 17,500 0.0355% | $55.57 | $972,475 | +3.61% | ||
| 2024-11-13 | Sale | director | 7,000 0.0142% | $55.54 | $388,780 | +3.61% | ||
| 2024-11-12 | Sale | director | 2,500 0.0051% | $57.50 | $143,750 | +2.64% | ||
| 2024-11-11 | Sale | director | 2,500 0.0049% | $55.00 | $137,500 | +0.85% | ||
| 2024-10-17 | Sale | President and CEO | 17,500 0.0354% | $40.34 | $705,950 | +38.95% | ||
| 2024-10-16 | Sale | President and CEO | 17,500 0.0335% | $41.38 | $724,150 | +36.90% | ||
| 2024-10-16 | Sale | director | 5,833 0.0112% | $41.36 | $241,253 | +36.90% | ||
| 2024-10-02 | Sale | director | 5,833 0.0109% | $40.35 | $235,362 | +36.29% | ||
| 2024-10-01 | Sale | Principal Accounting Officer | 568 0.0011% | $41.90 | $23,799 | +36.67% | ||
| 2024-09-18 | Sale | director | 5,834 0.0117% | $45.54 | $265,680 | +5.79% | ||
| 2024-09-12 | Sale | President and CEO | 17,500 0.0354% | $43.90 | $768,250 | +6.84% | ||
| 2024-09-11 | Sale | President and CEO | 17,500 0.0355% | $43.37 | $758,975 | 0.00% | ||
| 2024-09-04 | Sale | director | 5,000 0.0103% | $48.58 | $242,900 | -3.34% | ||
| 2024-09-03 | Sale | Chief Medical Officer | 10,000 0.0207% | $49.83 | $498,300 | -5.24% | ||
| 2024-08-15 | Sale | President and CEO | 17,500 0.0363% | $46.24 | $809,200 | 0.00% | ||
| 2024-08-14 | Sale | President and CEO | 17,500 0.0355% | $45.17 | $790,475 | 0.00% |
Insider Historical Profitability
| Colangelo Dominick | President and CEO | 220937 0.4476% | $56.50 | 1 | 35 | +18.13% |
| ARMSTRONG R DOUGLAS PHD | Chairman and CEO | 573763 1.1624% | $56.50 | 2 | 5 | <0.0001% |
| MAYLEBEN TIMOTHY M | President and CEO | 133000 0.2695% | $56.50 | 9 | 0 | +21.76% |
| MICHEL GERARD J | CFO and VP, Corp. Development | 123182 0.2496% | $56.50 | 1 | 12 | +18.13% |
| CRESSWELL RONALD M | director | 40000 0.081% | $56.50 | 2 | 0 | +3.5% |
Institutional Investor Ownership
| BlackRock | $414.57M | 16.4 | 7.97M | +0.41% | +$1.69M | 0.01 | |
| Brown Capital Management | $257.55M | 10.19 | 4.95M | -27.39% | -$97.17M | 4.58 | |
| The Vanguard Group | $177.57M | 7.02 | 3.41M | +1.17% | +$2.05M | <0.01 | |
| State Street | $167.23M | 6.61 | 3.21M | +20.63% | +$28.6M | 0.01 | |
| Conestoga Capital Advisors, LLC | $121.27M | 4.8 | 2.33M | -0.37% | -$449,973.00 | 1.78 |